
Topic
Payer Policy
Medicare, commercial payer, PBM, and formulary-policy moves that shape launch curves and gross-to-net.

Pricing & Access· May 27, 2026 · 10 min read

Pricing & Access· May 27, 2026 · 12 min read
Trikafta and Alyftrek CFTR modulator access guide

Pricing & Access· May 27, 2026 · 9 min read
Trodelvy access guide for breast cancer coverage
By Ran Chen#Oncology#ADC#Prior Authorization

Pricing & Access· May 27, 2026 · 12 min read
Tysabri and Tyruko natalizumab biosimilar access guide

Pricing & Access· May 27, 2026 · 15 min read
Vyvgart vs Vyvgart Hytrulo access guide

Biosimilars· May 27, 2026 · 11 min read
Xolair and Omlyclo omalizumab access guide

Pricing & Access· May 25, 2026 · 9 min read
CGRP inhibitor access landscape: eight drugs, coverage, and payer criteria in 2026
By Ran Chen#CGRP#CNS and Migraine#Coverage Access

Pricing & Access· May 25, 2026 · 9 min read
PCSK9 inhibitor access landscape: Repatha, Praluent, Leqvio, and Lerochol in 2026
By Ran Chen#PCSK9#Cardiovascular#Coverage Access

Pricing & Access· May 24, 2026 · 12 min read
IL-23 inhibitor access landscape: Skyrizi, Stelara, Tremfya, Omvoh, and Ilumya in 2026
By Ran Chen#Immunology#IL-23 Inhibitor#Coverage Access

Pricing & Access· May 24, 2026 · 12 min read
JAK inhibitor access landscape: Rinvoq, Xeljanz, Olumiant, Leqselvi, and Cibinqo in 2026
By Ran Chen#JAK Inhibitor#Immunology#Coverage Access